Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2025-03-14 AGM Information
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
Diasorin S.p.A. - Ordinary Shareholders' Meeting April 28, 2025 - Notice of call
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Call to the Ordinary Shareholders' Meeting" for Diasorin S.p.A. on April 28, 2025. It details the agenda, which includes the approval of 2024 financial statements, remuneration policy, appointment of the Board of Directors and Auditors, and authorization for share plans/treasury shares. This content is characteristic of the official announcement preceding a general meeting, which falls under the definition of AGM Information (AGM-R). Although it mentions financial statements (10-K/IR items), the primary purpose and format are that of a formal meeting notice.
2025-03-14 English
Diasorin S.p.A. – Assemblea Ordinaria degli Azionisti 28 aprile 2025 – Avviso di convocazione
Proxy Solicitation & Information Statement Classification · 99% confidence The document is an official notice titled "Diasorin S.p.A. – Assemblea Ordinaria degli Azionisti 28 aprile 2025 – Avviso di convocazione" (Notice of Convocation for the Ordinary Shareholders' Meeting on April 28, 2025). It details the agenda (Bilancio, Remuneration Policy, Board/Statutory Auditor nominations, incentive plans, share buyback authorization) and the procedures for remote participation via a designated representative, referencing Italian regulations (TUF). This content is characteristic of materials issued to shareholders to inform them about an upcoming meeting and solicit their participation/votes, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it concerns an AGM, the primary function here is the formal notice and procedural instructions, not the AGM presentation itself (AGM-R) or the final voting results (DVA).
2025-03-14 Italian
Diasorin FY 2024 Results Presentation
Earnings Release Classification · 98% confidence The document is explicitly titled "FY 2024 RESULTS" and contains detailed financial highlights for Q4 2024 and FY 2024, including Revenues, Adjusted EBITDA, Adjusted EBIT, and Net Profit figures. It also includes a section on "MANAGERIAL OUTLOOK ON Q4 AND FY 2024 REVENUES" and extensive forward-looking statements and product development updates. This content structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often accompanied by a presentation deck like this one. While it contains detailed financials, it is presented as a summary/presentation accompanying the results announcement, rather than the comprehensive, audited Annual Report (10-K) or a standalone Audit Report (AR). It is too detailed for just a Report Publication Announcement (RPA) and clearly presents the results themselves. FY 2024
2025-03-14 English
The Board of Directors of Diasorin SpA approves FY2024 Results with revenues and net profit in expansion compared to Previous Year; Proposed Ordinary Dividend of € 1.20 per share
Earnings Release Classification · 98% confidence The document is a formal announcement dated March 14, 2025, detailing the approval of the company's FY2024 results, including revenues, net profit, and a proposed dividend (€ 1.20 per share). It contains key financial highlights, tables of results (FY2023 vs FY2024), commentary on business segments, and mentions the approval of several reports (Consolidated Financial Statements, Corporate Governance Report, Remuneration Report) and the calling of a Shareholders' Meeting. The core content is the summary of annual financial performance and related corporate actions. This strongly indicates an Earnings Release (ER) or a document summarizing the annual results, which often precedes the full 10-K filing. Since it provides detailed financial figures and commentary on the full year, it fits the description of an Earnings Release (ER) which is the initial announcement of periodical financial results (in this case, annual results). It is not the full 10-K, nor is it merely an announcement of a report (RPA), as it contains the results themselves. It also mentions the approval of the Corporate Governance Report and Remuneration Report, but the primary focus is the financial performance summary. FY 2024
2025-03-14 English
Registration and publication of the minutes of the shareholders' meeting. Withdrawal right.
AGM Information Classification · 99% confidence The document is an official announcement from Diasorin S.p.A. dated March 3, 2025. The subject ('Oggetto') explicitly states: 'Registration and publication of the minutes of the shareholders' meeting. Withdrawal right.' The text confirms that the minutes of the extraordinary shareholders' meeting (held on February 28, 2025) have been registered and made available to the public. This announcement concerns the formal conclusion and dissemination of a shareholder meeting's decisions and related rights (withdrawal right). This strongly aligns with the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) follow-up documentation. Since the document is an announcement about the registration and publication of the minutes of a shareholders' meeting, the most appropriate classification is AGM-R (AGM Information), as it directly relates to the formal proceedings and outcomes of a general meeting.
2025-03-03 English
Iscrizione e pubblicazione del verbale assembleare. Diritto di recesso.
AGM Information Classification · 95% confidence The document is an official communication from Diasorin S.p.A. (Informazione Regolamentata) dated March 3, 2025. The subject ('Oggetto') is the 'Iscrizione e pubblicazione del verbale assembleare. Diritto di recesso' (Registration and publication of the shareholders' meeting minutes. Right of withdrawal). It explicitly states that the minutes of the Extraordinary Shareholders' Meeting (Assemblea Straordinaria) held on February 28, 2025, have been registered and made available to the public, including details about the right of withdrawal for dissenting shareholders. This document is not the full minutes, nor is it a general earnings release or annual report. It is an announcement concerning the formal conclusion and publication of a shareholder meeting's outcome, specifically mentioning the registration of the minutes and shareholder rights related to the resolutions passed. This aligns best with an announcement related to shareholder meetings and voting outcomes, which points towards AGM-R (AGM Information) or potentially RNS (Regulatory Filings) if the AGM-R definition is too narrow. Since the core content is the publication of the minutes from an 'assemblea straordinaria' (Extraordinary Shareholders' Meeting) and details related to voting outcomes (right of withdrawal), AGM-R is the most specific fit, as AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)'—though this is an Extraordinary meeting, the nature of the filing is directly related to shareholder meeting outcomes. Given the specific mention of the 'verbale assembleare' (meeting minutes) and shareholder rights following a vote, AGM-R is the primary candidate, although RNS is a strong secondary fallback if the meeting was not the *Annual* General Meeting. Since the document focuses entirely on the formalization of the meeting's results, AGM-R is chosen as the most descriptive category for shareholder meeting documentation.
2025-03-03 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.